AAPL343.46+1.46 (+0.43%) ▲|ABBV285.42+2.02 (+0.71%) ▲|ABT104.89+0.21 (+0.20%) ▲|ACN229.68+4.76 (+2.12%) ▲|ADBE245.20-6.47 (-2.57%) ▼|AMAT409.29-20.72 (-4.82%) ▼|AMD528.75-33.48 (-5.95%) ▼|AMGN432.49-1.54 (-0.35%) ▼|AMT185.27+3.91 (+2.16%) ▲|AMZN250.00-4.76 (-1.87%) ▼|AVGO328.75-15.58 (-4.52%) ▼|AXP313.59-0.28 (-0.09%) ▼|BA190.21+1.48 (+0.78%) ▲|BAC51.23-0.47 (-0.91%) ▼|BKNG163.45-2.35 (-1.42%) ▼|BLK1,134.38+13.60 (+1.21%) ▲|BMY59.75-0.82 (-1.35%) ▼|BNY143.30+1.21 (+0.85%) ▲|BRK-B532.02+6.34 (+1.21%) ▲|C124.26+1.05 (+0.85%) ▲|CAT730.76-4.88 (-0.66%) ▼|CL94.11+1.44 (+1.55%) ▲|CMCSA21.90+0.13 (+0.60%) ▲|COF201.74+2.88 (+1.45%) ▲|COP146.51+4.78 (+3.37%) ▲|COST989.11+11.10 (+1.14%) ▲|CRM240.70-6.04 (-2.45%) ▼|CSCO107.39-2.46 (-2.24%) ▼|CVS92.36-0.22 (-0.24%) ▼|CVX224.99+5.67 (+2.59%) ▲|DE641.86-8.81 (-1.35%) ▼|DHR229.04-2.46 (-1.06%) ▼|DIS110.59-0.09 (-0.08%) ▼|DUK121.47+2.59 (+2.18%) ▲|EMR161.47-0.68 (-0.42%) ▼|FDX293.55-1.99 (-0.67%) ▼|GD344.23+7.20 (+2.14%) ▲|GE313.83+1.83 (+0.59%) ▲|GEV921.20-5.24 (-0.57%) ▼|GILD156.19-1.18 (-0.75%) ▼|GM83.96+0.30 (+0.36%) ▲|GOOG336.91-8.00 (-2.32%) ▼|GOOGL340.59-8.63 (-2.47%) ▼|GS881.26-10.02 (-1.12%) ▼|HD309.63+1.39 (+0.45%) ▲|HON211.41+0.91 (+0.43%) ▲|IBM232.14-1.98 (-0.85%) ▼|INTC89.85-5.52 (-5.79%) ▼|INTU325.15-5.02 (-1.52%) ▼|ISRG426.70-1.16 (-0.27%) ▼|JNJ255.56+2.28 (+0.90%) ▲|JPM339.72+4.19 (+1.25%) ▲|KO93.90+1.90 (+2.07%) ▲|LIN498.43+5.21 (+1.06%) ▲|LLY1,257.03+5.42 (+0.43%) ▲|LMT552.09+19.45 (+3.65%) ▲|LOW197.38+1.66 (+0.85%) ▲|LRCX263.94-13.52 (-4.87%) ▼|MA617.42+1.10 (+0.18%) ▲|MCD242.97+0.47 (+0.19%) ▲|MDLZ63.91+0.88 (+1.40%) ▲|MDT94.75-0.70 (-0.73%) ▼|META709.33-27.40 (-3.72%) ▼|MMM164.75-0.58 (-0.35%) ▼|MO75.11+1.27 (+1.72%) ▲|MRK145.95+0.76 (+0.52%) ▲|MS180.57-1.53 (-0.84%) ▼|MSFT529.05-10.39 (-1.93%) ▼|MU878.84-52.40 (-5.63%) ▼|NEE79.80+0.84 (+1.06%) ▲|NFLX70.53-2.08 (-2.86%) ▼|NKE37.13-0.01 (-0.03%) ▼|NOW141.97-6.60 (-4.44%) ▼|NVDA214.13-3.10 (-1.43%) ▼|ORCL128.23-6.24 (-4.64%) ▼|PEP131.49+3.11 (+2.42%) ▲|PFE29.58+0.14 (+0.48%) ▲|PG159.35+2.27 (+1.45%) ▲|PLTR186.03-14.47 (-7.22%) ▼|PM205.20+5.30 (+2.65%) ▲|QCOM172.11-6.29 (-3.53%) ▼|RTX193.92+6.97 (+3.73%) ▲|SBUX97.52+0.64 (+0.66%) ▲|SCHW91.96-2.20 (-2.34%) ▼|SO91.18+2.00 (+2.24%) ▲|SPG205.44+2.05 (+1.01%) ▲|T23.44-0.06 (-0.26%) ▼|TMO690.00-6.49 (-0.93%) ▼|TMUS159.10+2.07 (+1.32%) ▲|TSLA354.72-7.72 (-2.13%) ▼|TXN276.48-2.64 (-0.95%) ▼|UBER70.35-0.92 (-1.29%) ▼|UNH401.43-5.24 (-1.29%) ▼|UNP289.04+0.33 (+0.11%) ▲|UPS97.48-0.35 (-0.36%) ▼|USB58.73+1.34 (+2.33%) ▲|V402.61+2.86 (+0.72%) ▲|VZ44.79+0.39 (+0.88%) ▲|WFC83.87+1.12 (+1.35%) ▲|WMT118.81+0.94 (+0.80%) ▲|XOM178.98+4.30 (+2.46%) ▲|AAPL343.46+1.46 (+0.43%) ▲|ABBV285.42+2.02 (+0.71%) ▲|ABT104.89+0.21 (+0.20%) ▲|ACN229.68+4.76 (+2.12%) ▲|ADBE245.20-6.47 (-2.57%) ▼|AMAT409.29-20.72 (-4.82%) ▼|AMD528.75-33.48 (-5.95%) ▼|AMGN432.49-1.54 (-0.35%) ▼|AMT185.27+3.91 (+2.16%) ▲|AMZN250.00-4.76 (-1.87%) ▼|AVGO328.75-15.58 (-4.52%) ▼|AXP313.59-0.28 (-0.09%) ▼|BA190.21+1.48 (+0.78%) ▲|BAC51.23-0.47 (-0.91%) ▼|BKNG163.45-2.35 (-1.42%) ▼|BLK1,134.38+13.60 (+1.21%) ▲|BMY59.75-0.82 (-1.35%) ▼|BNY143.30+1.21 (+0.85%) ▲|BRK-B532.02+6.34 (+1.21%) ▲|C124.26+1.05 (+0.85%) ▲|CAT730.76-4.88 (-0.66%) ▼|CL94.11+1.44 (+1.55%) ▲|CMCSA21.90+0.13 (+0.60%) ▲|COF201.74+2.88 (+1.45%) ▲|COP146.51+4.78 (+3.37%) ▲|COST989.11+11.10 (+1.14%) ▲|CRM240.70-6.04 (-2.45%) ▼|CSCO107.39-2.46 (-2.24%) ▼|CVS92.36-0.22 (-0.24%) ▼|CVX224.99+5.67 (+2.59%) ▲|DE641.86-8.81 (-1.35%) ▼|DHR229.04-2.46 (-1.06%) ▼|DIS110.59-0.09 (-0.08%) ▼|DUK121.47+2.59 (+2.18%) ▲|EMR161.47-0.68 (-0.42%) ▼|FDX293.55-1.99 (-0.67%) ▼|GD344.23+7.20 (+2.14%) ▲|GE313.83+1.83 (+0.59%) ▲|GEV921.20-5.24 (-0.57%) ▼|GILD156.19-1.18 (-0.75%) ▼|GM83.96+0.30 (+0.36%) ▲|GOOG336.91-8.00 (-2.32%) ▼|GOOGL340.59-8.63 (-2.47%) ▼|GS881.26-10.02 (-1.12%) ▼|HD309.63+1.39 (+0.45%) ▲|HON211.41+0.91 (+0.43%) ▲|IBM232.14-1.98 (-0.85%) ▼|INTC89.85-5.52 (-5.79%) ▼|INTU325.15-5.02 (-1.52%) ▼|ISRG426.70-1.16 (-0.27%) ▼|JNJ255.56+2.28 (+0.90%) ▲|JPM339.72+4.19 (+1.25%) ▲|KO93.90+1.90 (+2.07%) ▲|LIN498.43+5.21 (+1.06%) ▲|LLY1,257.03+5.42 (+0.43%) ▲|LMT552.09+19.45 (+3.65%) ▲|LOW197.38+1.66 (+0.85%) ▲|LRCX263.94-13.52 (-4.87%) ▼|MA617.42+1.10 (+0.18%) ▲|MCD242.97+0.47 (+0.19%) ▲|MDLZ63.91+0.88 (+1.40%) ▲|MDT94.75-0.70 (-0.73%) ▼|META709.33-27.40 (-3.72%) ▼|MMM164.75-0.58 (-0.35%) ▼|MO75.11+1.27 (+1.72%) ▲|MRK145.95+0.76 (+0.52%) ▲|MS180.57-1.53 (-0.84%) ▼|MSFT529.05-10.39 (-1.93%) ▼|MU878.84-52.40 (-5.63%) ▼|NEE79.80+0.84 (+1.06%) ▲|NFLX70.53-2.08 (-2.86%) ▼|NKE37.13-0.01 (-0.03%) ▼|NOW141.97-6.60 (-4.44%) ▼|NVDA214.13-3.10 (-1.43%) ▼|ORCL128.23-6.24 (-4.64%) ▼|PEP131.49+3.11 (+2.42%) ▲|PFE29.58+0.14 (+0.48%) ▲|PG159.35+2.27 (+1.45%) ▲|PLTR186.03-14.47 (-7.22%) ▼|PM205.20+5.30 (+2.65%) ▲|QCOM172.11-6.29 (-3.53%) ▼|RTX193.92+6.97 (+3.73%) ▲|SBUX97.52+0.64 (+0.66%) ▲|SCHW91.96-2.20 (-2.34%) ▼|SO91.18+2.00 (+2.24%) ▲|SPG205.44+2.05 (+1.01%) ▲|T23.44-0.06 (-0.26%) ▼|TMO690.00-6.49 (-0.93%) ▼|TMUS159.10+2.07 (+1.32%) ▲|TSLA354.72-7.72 (-2.13%) ▼|TXN276.48-2.64 (-0.95%) ▼|UBER70.35-0.92 (-1.29%) ▼|UNH401.43-5.24 (-1.29%) ▼|UNP289.04+0.33 (+0.11%) ▲|UPS97.48-0.35 (-0.36%) ▼|USB58.73+1.34 (+2.33%) ▲|V402.61+2.86 (+0.72%) ▲|VZ44.79+0.39 (+0.88%) ▲|WFC83.87+1.12 (+1.35%) ▲|WMT118.81+0.94 (+0.80%) ▲|XOM178.98+4.30 (+2.46%) ▲|
7.1 C
New York
Sunday, October 18, 2026

Tag: X

newssourceFORcompanycontentinformation1releasesmarket

82% of Adults with Type 2 Diabetes Not on Insulin Improve Blood Glucose Levels with Continuous Glucose Monitoring

New Study Highlights Potential of CGM to Help Patients Improve Diabetes Management in Primary Care SettingsNEW ORLEANS, June 6, 2026 /PRNewswire/ -- A new...

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions

Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic...

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more...

Adults with type 2 diabetes on semaglutide 1 mg whose dose was increased to 2 mg were as likely to reach an HbA1c level...

Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes

New research supports monthly dosing as a next‑generation opportunity to improve weight lossNEW ORLEANS, June 6, 2026 /PRNewswire/ -- New data highlight the potential...

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect earlyKetone monitoring is not yet routine in diabetes care, which may...

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes 
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes

Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach to Early IdentificationNEW ORLEANS, June 5,...

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to...

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin UseNEW ORLEANS, June 5, 2026 /PRNewswire/ -- A...

Corgi Launches Suite of Six Fixed Income ETFs on Cboe BZX, Capping a Week of 50 Fund Launches

Corgi lists CGOV, CBIL, CUST, CIEI, CIVG, and CHYG - offering Treasury and corporate bond exposure across the yield curve at an expense ratio...

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 1, 2026 (the “Grant Date”), ORIC granted a total of 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees who began their employment with ORIC in May 2026.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsX

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers